Assertio Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ASSERTIO
ASSERTIO has two approved drugs.
There are eighteen US patents protecting ASSERTIO drugs.
There are forty-five patent family members on ASSERTIO drugs in fourteen countries.
Summary for Assertio
| International Patents: | 45 |
| US Patents: | 18 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Assertio
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | DISCN | Yes | No | 11,684,723 | ⤷ Get Started Free | Y | ⤷ Get Started Free | |||
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | DISCN | Yes | No | 12,357,642 | ⤷ Get Started Free | Y | ⤷ Get Started Free | |||
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | DISCN | Yes | No | 11,497,753 | ⤷ Get Started Free | Y | ⤷ Get Started Free | |||
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | DISCN | Yes | No | 8,480,631 | ⤷ Get Started Free | Y | ⤷ Get Started Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Assertio
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | 7,776,015 | ⤷ Get Started Free |
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-008 | Mar 24, 2016 | RE44847 | ⤷ Get Started Free |
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | 6,746,429 | ⤷ Get Started Free |
| Assertio Speclty | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | RE44847 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Assertio Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2020051317 | ⤷ Get Started Free |
| Japan | 2021536466 | ⤷ Get Started Free |
| Brazil | PI0614025 | ⤷ Get Started Free |
| Canada | 3110997 | ⤷ Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
